Krause T, Fleming A, Hurst M, Zema C, Costello J, Hawe E, Ling C. Prognostic factors and surrogate endpoints in obstructive hypertrophic cardiomyopathy: a systematic literature review. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S36. doi: 10.1016/j.jval.2023.09.189
Gildea L, Mordin M, Long J, D'Souza V, Kinderås M, Warttig S, Hartley L, Ling C. Understanding how health technology assessment bodies select medical technology for review: results of an online survey. Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S432. doi: 10.1016/j.jval.2023.09.2258
D'Souza V, Gildea L, Mordin M, Long J, Kinderås M, Ling C, Warttig S, Hartley L. Differences and similarities of health economic evaluation for medical technologies by HTA bodies. Poster presented at the ISPOR Europe 2023; November 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S438. doi: 10.1016/j.jval.2023.09.2287
Mordin M, Gildea L, Long J, D'Souza V, Kinderås M, Ling C, Warttig S, Hartley L. What evidence should medical technology companies expect HTA bodies to review? Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S431. doi: 10.1016/j.jval.2023.09.2254
Mordin M, Warttig S, Gildea L, Long J, D'Souza V, Kinderås M, Ling C, Hartley L. Digging into the medical technology HTA process in Tunisia. Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S429. doi: 10.1016/j.jval.2023.09.2242
Lanne G, Kinderås M, Ling C, Brodtkorb TH. How much does TLV value rarity? A review of reimbursement decisions on orphan drugs in Sweden from 2017 through 2022. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S201. doi: 10.1016/j.jval.2023.09.1028
Kinderås M, Gildea L, Mordin M, Long J, D'Souza V, Ling C, Warttig S, Hartley L. Submission process and requirements of Nordic health technology assessment organisations for medical technologies: results of an online survey. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S435. doi: 10.1016/j.jval.2023.09.2272
Hartley L, Gildea L, Mordin M, Long J, D'Souza V, Kinderås M, Ling C, Warttig S. Does real-world evidence play a role in decision-making by HTA bodies for medical technologies? Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S434-5. doi: 10.1016/j.jval.2023.09.2271
Mordin M, Gildea LJ, Warttig S, Costello J, D'Souza V, Kinderås M, Ling C, Marcano Belisario J. HTA processes for medical technologies across the world – are all hurdles the same? Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S272-3. doi: 10.1016/j.jval.2023.03.1503
Costello J, D'Souza V, Gildea L, Kinderås M, Ling C, Belisario JM, Warttig S. Process and requirements for submitting nonpharmaceutical medical technologies to health technology assessment authorities. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S386. doi: 10.1016/j.jval.2022.09.1915
Warttig S, Ling C. Health technology assessment (HTA) methods for monoclonal antibodies for treatment and prevention of COVID-19. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S301. doi: 10.1016/j.jval.2022.09.1486
Aronsson M, Ling C, Stevenson A, Brodtkorb TH. Submission process and requirements of Nordic health technology assessment (HTA) authorities for hospital drugs - implications for market access strategy. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).
Pearson I, Stevenson A, Krieger T, Ling C. What is the role of the company evidence submission in National Institute for Health and Care Excellence (NICE) multiple technology appraisals? Poster presented at the ISPOR 2019 European Conference; November 5, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).
Ling C, Nuabor W, Lyall M, Stevenson A. Review of possible causes of variation in National Institute for Health and Care Excellence (NICE) technology appraisals. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Suppl 3):S200.
Chirila C, Mitra D, Colosia A, Ling C, Odom D, Iyer S, Kaye JA. Efficacy of palbociclib combinations versus endocrine therapies in advanced/ metastatic breast cancer: network meta-analysis. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A710.
Hogue SL, Bjoerk B, Walker A, Balp M, Fernandez MM, Quijano M, Ling CS, Heyes AE. Evidence-based market access value resource: navigating the hurdles for a biologic obtaining a license in a second indication in key European countries. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam. [abstract] Value Health. 2014 Nov; 17(7):A431-2.
Woods MS, Kiri S, Ling CS, McCrink L, Zimovetz E, Hass B. A systematic review of economic evidence in hepatitis c: methods used in recent economic evaluations. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A579.
Woods MS, Kiri S, Ling CS, McCrink L, Zimovetz E, Hass B. A systematic review of economic evidence in hepatitis c: an overview of cost, utility, and cost-effectiveness data. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A349.
Ainsworth C, Kiri S, Ling CS, Heyes AE, Hass B. The global burden, incidence, and prevalence of chronic hepatitis c. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A342.
Ling CS, Weisgerber-Kriegl U, Njue AI, Heyes A, Kaye J. The effect of positive margins on outcomes in breast cancer. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A394.
DiBenedetti D, Coles T, Ling CS, Sharma T, Pericleous L. Web-based study of patients and caregivers in the United States and Canada: perspectives on improvements in stability of factor viii products for hemophilia a. Poster presented at the 2013 ISPOR 18th Annual International Meeting; April 30, 2013. [abstract] Value Health. 2013 May; 16(3):A121.
Sennfalt K, Ling CS, Pericleous L, Sbarigia U, Gatta F, Kolasa K, Chamberlain G, Pandit P, Zagorska G. The economic burden of post-transplant events in renal transplant patients in UK, Italy, Netherlands, Poland and Belgium. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research; 2011. [abstract] Value Health. 2011 Nov; 14(7):A262-3.